Related Experiment Video
Updated: Sep 8, 2025
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
miR-27 and miR-124 target AR coregulators in prostate cancer: Bioinformatics and in vitro analysis
Mohammad Hassan Jafari Najaf Abadi1, Mohsen Khorashadizadeh2, Hossein Zarei Jaliani3
1Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
The inadequate efficacy of the current treatments for metastatic prostate cancer has directed efforts to the discovery of novel therapies. MicroRNAs (miRNAs) have been considered potential therapeutic agents due to their ability to control gene expression and cellular pathways. The accurate identification of genes and pathways which are targeted by a miRNA is the first step in the therapeutic use of these molecules. In this regard, there are multiple experimental and computational methods to predict and confirm the miRNA-mRNA relationships. The targeting the androgen receptor (AR) indirectly as the most important mediator of prostate cancer has been posited to both control the disease and prevent resistance to treatment. This study aimed to identify miRNAs targeting AR coregulators. For this purpose, we examined target genes by combining miRNA-mRNA computational and experimental data from various databases. miR-27a-3p and miR-124 displayed the highest scores and were selected as miRNAs with the potential to target candidate genes. Next, three cell lines of prostate cancer including PC3, LNCAP, and DU145 were transfected with plasmids which were expressed these selected miRNAs. Then, the gene expression and cell cycle analysis were performed. A decrease was observed in cell viability in all three cell lines than the cells transfected with backbone plasmid. Furthermore, the findings indicated that miR-27a-3p and miR-124 led to a significant decrease in the expression of all genes that were studied in PC3 cell line. In addition, miR-124 caused significant the cellular arrest in the G0/G1 stage, while for miR-27a-3p, this arrest occurred was in the G2/M stage. Our results indicated that the function of a unique miRNA could be different in different cell lines with particular cancer phenotype based on the cell line stage. These findings offer the possibility of employing the miR-124 and miR-27a-3p as therapeutic agents for prostate cancer treatment.
Insights
New research identifies microRNAs (miRNAs) miR-124 and miR-27a-3p as potential treatments for metastatic prostate cancer by targeting key genes and affecting cell cycles, offering hope for improved therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Current metastatic prostate cancer treatments have limited efficacy, necessitating novel therapeutic strategies.
- MicroRNAs (miRNAs) show promise as therapeutic agents due to their regulatory roles in gene expression and cellular pathways.
- Targeting the androgen receptor (AR) pathway is crucial for prostate cancer treatment and overcoming resistance.
Purpose of the Study:
- To identify specific microRNAs (miRNAs) that target androgen receptor (AR) coregulators in prostate cancer.
- To evaluate the therapeutic potential of identified miRNAs in prostate cancer cell lines.
Main Methods:
- Computational and experimental data from various databases were combined to predict miRNA-mRNA interactions.
- Selected miRNAs (miR-27a-3p and miR-124) were transfected into three prostate cancer cell lines (PC3, LNCAP, DU145).
- Gene expression and cell cycle analyses were performed post-transfection.
Main Results:
- Both miR-27a-3p and miR-124 reduced cell viability across all tested prostate cancer cell lines.
- These miRNAs significantly decreased the expression of target genes in the PC3 cell line.
- miR-124 induced G0/G1 cell cycle arrest, while miR-27a-3p caused G2/M arrest, indicating cell-type-specific effects.
Conclusions:
- miR-124 and miR-27a-3p demonstrate potential as therapeutic agents for prostate cancer.
- The functional impact of a miRNA can vary depending on the specific prostate cancer cell line and its stage.
- These findings support the development of miRNA-based therapies for prostate cancer, potentially overcoming treatment resistance.
